Tailor-Made vaccine aims to stop cancer return in High-Risk patients
Disease control
Completed
This early-phase study tested a personalized immunotherapy (iNeo-Vac-P01) in 6 patients with stage III colorectal or non-small cell lung cancer who had already completed surgery and standard adjuvant therapy. The vaccine was designed to target unique neoantigens from each patient…
Phase: PHASE1 • Sponsor: Ying Yuan, MD • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC